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Abstract
Background: Chronic kidney disease (CKD) is a significant public health problem that leads to end-stage renal disease
(ESRD) with as many as 2 million people predicted to need therapy worldwide by 2010. Obesity is a risk factor for CKD and
leptin, the obesity hormone, correlates with body fat mass and markers of renal function. A number of clinical and
experimental studies have suggested a link between serum leptin and kidney disease. We hypothesised that variants in the
leptin gene (LEP) may be associated with markers of CKD in indigenous black Africans.
Methodology/Principal Findings: Black South Africans of Xhosa (distinct cultural Bantu-speaking population) descent were
recruited for the study and four common polymorphisms of the LEP (rs7799039, rs791620, rs2167270 and STS-U43653
[ENSSNP5824596]) were analysed for genotype and haplotype association with urine albumin-to-creatinine ratio (UACR),
estimated glomerular filtration rate (eGFR), Serum creatinine (Scr) and serum leptin level. In one of the four single nucleotide
polymorphisms (SNPs) we examined, an association with the renal phenotypes was observed. Hypertensive subjects with
the T allele (CT genotype) of the ENSSNP5824596 SNP had a significantly higher eGFR (p=0.0141), and significantly lower
Scr (p=0.0137). This was confirmed by haplotype analysis. Also, the haplotype GAAC had a modest effect on urine albumin-
to-creatinine ratio in normotensive subjects (p=0.0482).
Conclusions/Significance: These results suggest that genetic variations of the LEP may be associated with phenotypes that
are markers of CKD in black Africans.
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Introduction
Chronic kidney disease (CKD) is a significant public health
problem. CKD is irreversible and ultimately progresses to end-stage
renal disease(ESRD), projectedto affect2 million people worldwide
by 2010 worldwide [1,2]. Microalbuminuria, a reversible and early
measure of kidney disease marks the initiation of kidney disease and
is a significant predictor of cardiovascular events and all-cause
mortality in patients with diabetes, hypertension, and in the general
population [3,4]. Other measures of renal dysfunctions such as an
increase in serum creatinine (Scr) and a reduced estimated
glomerular filtration rate (eGFR) have also been shown to predict
cardiovascular disease [5]. Estimates of the NHANES III dataset
have shown that approximately 3 and 11% of the US population
have abnormal Scr levels or microalbuminuria, respectively [6,7].
Recently, obesity has been identified as a major driver for
progressive kidney injury [8,9]. A relative risk of 2.3 was reported of
incident ESRD or kidney disease-related death in morbidly obese
individuals who participated in the NHANES III survey [8]. Leptin
is the obesity hormone synthesized mainly by white adipose tissue in
humans [10] and its serum level shows strong correlation with body
fat mass [11]. Mutations in the leptin gene (LEP) have been reported
to cause severe obesity [10,12] and may also contribute to the
complications associated with obesity. The potential role of serum
leptin in the pathogenesis of CKD has become increasingly
recognised and a number of studies have demonstrated correlations
between serum leptin and markers of renal function [13,14]. Leptin
stimulates the proliferation of cultured glomerular endothelial cells
and induces mRNA expression and protein secretion of transform-
ing growth factor-b1 (TGF-b1). Long-term infusion with leptin (3
weeks) has led to increased glomerular expression of type IV
collagen [15]. Leptin has also been shown to stimulate synthesis of
typeI collagenin mesangialcells and typeIV collagen inglomerular
endothelial cells which contributes to extracellular matrix deposi-
tion,glomerulosclerosis,and proteinuria[16].Itis therefore possible
that genetic variation/s in the LEP, possibly related to variation in
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9086serum leptin concentration may be associated with markers of
kidney disease such as urine albumin-to-creatinine ratio (UACR),
Scr and eGFR. We therefore hypothesized that polymorphisms of
the LEP may have significant effects on markers of renal function in
black Africans.
Methods
The population sampling of this study, which is part of a larger
study to determine the effects of obesity through the metabolic
syndrome on kidney disease in an indigenous African population,
was of a cross-sectional design and was carried out in Cape Town
between May 2005 and July 2006. The study was approved by the
joint Research Ethics Committee (REC) of the University of Cape
Town and Groote Schuur Hospital. Written informed consent
(approved by our REC) was obtained from each subject before
they could enter the study. The method of recruitment has been
previously described [14]. Briefly, two hundred and fifty three
(253) ambulatory hypertensive subjects attending the Guguletu
hypertension clinic and eighty-three (83) normotensive relatives in
the community were recruited for the study. Although 336 subjects
were recruited for the entire study, the sample sizes for the
different single nucleotide polymorphisms (SNPs) that were
examined differed and were fewer than that of the entire study
population due to variation in the availability of high quality
DNA, and incomplete successfully genotyping. We chose to study
these non-coding polymorphisms because they capture the
common haplotype variation across the LEP (figure 1) and also
because they have been the commonly studied of the LEP SNPs in
other populations, therefore providing a basis for comparison with
our population.
The subjects were all of the same indigenous southern African
tribal/cultural population group, namely of Xhosa origin, to
ensure a homogenous population and to avoid confounding by
population admixture which may lead to spurious results in gene
association studies of unrelated individuals [17]. A questionnaire
was administered to all participants to obtain relevant demo-
graphic information. Height, weight, waist and hip circumference
were obtained. Body mass index was calculated from weight (kg)
divided by height squared (m
2). Blood pressure was measured
in all the subjects using the same validated mercury sphygmoma-
nometer. The average of 2 blood pressure measurements taken
at least 2 minutes apart in the sitting position after about 5–10
minutes rest was recorded. Blood was drawn in the fasting state
for routine chemistry including creatinine, lipids, glucose and for
assay of leptin. Spot urine was also taken to measure the urine
albumin-to-creatinine ratio (UACR). For all the tests, conventional
assays were used in the chemical pathology laboratory on auto-
analysers with appropriate quality control. The eGFR was cal-
culated using the Modification of Diet in Renal Disease (MDRD)
equation [18]:
eGFR~186 x SCr ðÞ
{1:154 x age ðÞ
{0:203 x0 :742 if female ðÞ
x1 :210 if black ðÞ :
Serum leptin was measured using a commercially available
human leptin radioimmunoassay kit (Linco Research, St. Charles,
MO) with sensitivity 0.5 ng/ml, intra-assay precision 3.4–8.3%,
and inter-assay precision 3.6–6.2%. All genetic analysis was
carried out in the Division of Human Genetics at the University of
Cape Town. Genomic DNA was isolated from peripheral blood
lymphocytes using the Puregene DNA Isolation Kit (Gentra
Systems, USA) according to the manufacturer’s protocol. Poly-
merase Chain Reaction (PCR) was carried out individually for the
four SNPs being tested. This was followed by restriction enzyme
(RE) digest of the PCR products (table S1, S2, S3, S4). The
primers (forward and reverse) used for the SNPs as well as the
restriction enzymes used in the digest are shown in Table 1.
Figure 1. Position of four polymorphisms typed across the leptin (LEP) gene on chromosome 7. Dark shading indicates coding sequence.
doi:10.1371/journal.pone.0009086.g001
Table 1. Primers and the restriction enzymes used for genotyping.
SNP Forward Primer Reverse Primer Restriction Enzyme
rs7799039 59 TTTCCTGTAATTTTCCCGTGAG 39 59 AAAGCAAAGACAGGCATAAAAA 39 HhaI
rs791620 59 CAACGAGGGCGCAGCCGTAT 39 59 AGTGTGCACCTCGCGGGGCCT 39 AscI
rs2167270 59 GCCCCGCGAGGTGCACACTG 39 59 GGGCCCTGTGGCCTGCCAAG 39 MspA1I
ENSSNP5824596 59 CGACCTGGAGAACCTCCG 39 59 GTCCTGGATAAGGGGTGT 39 HpyCH4IV
doi:10.1371/journal.pone.0009086.t001
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quantile normalised for analysis, consequently, only age and
gender were adjusted for in the analysis. Untransformed values are
summarised, for ease of interpretation. We had to use mixed-
effects models for comparing the hypertensive to the normotensive
groups, to enable us adjust for the relatedness between the
normotensives and the hypertensives.
All genetic association analyses were stratified between
hypertensive and normotensives, and adjusted for age and gender.
We used linear models on quantile normalised traits. Genotypes
were coded as categories (genotype; 2 degrees of freedom) and also
as number of minor alleles (allelic; 1 degree of freedom). In cases
where no minor allele homozygotes were observed, these analyses
were equivalent. Haplotypes were imputed and analysed using an
EM algorithm and generalised linear models [19]. We tested
haplotype association with hypertension status, as well as for
quantile normalised phenotypes stratified by hypertension diag-
nosis. We tested all possible haplotypes, from two to all four, from
adjacent positions. R and R packages were used for statistical
modelling; nlme for mixed-effects and haplo.stats for haplotype
analyses [19] (R is a free software environment for statistical
computing and graphics available from http://www.r-project.org).
Results
The baseline features (demographic, clinical and biochemical) of
all the participating subjects are summarised in table 2, stratified
by diagnostic group. The median values of kidney disease
phenotypes (Scr, eGFR and UACR) were not significantly
different between the hypertensive and normotensive individuals.
The genotype frequencies of the different polymorphisms are
summarised in table 3 and agree closely with the genotype
frequencies described at this polymorphism in Yoruba Africans
in the Hapmap project [20]. All the typed SNPs were in Hardy-
Weinberg equilibrium in the normotensive group (p,0.01),
however, the SNP rs2167270 was not in Hardy-Weinberg
equilibrium in the hypertensive subjects. No significant association
was detected between hypertension status, obesity, the metabolic
syndrome, hyperleptinaemia or gender and any of the 4
polymorphisms studied. In the hypertensive group, two pheno-
types (Scr and eGFR), were associated with ENNSNP5824596,
with the T allele significantly increasing eGFR (p=0.0137) and
decreasing Scr (p=0.0186) (Table 4).
The haplotypes GCGC and GCAC occurred more frequently
than other haplotypes in the hypertensive and normotensive
groups, respectively (Table 5). In the hypertensive group,
haplotype GCAT yielded significantly higher values of eGFR
than GCGC (p=0.0278). The 3-way haplotype, excluding the first
SNP, showed a similar pattern with CAT being associated with
significantly higher values of eGFR than both CGC (p=0.0255).
In the last two polymorphisms, AT was also associated with
significantly higher eGFR than GC (p=0.0233) (Table 6).
In the hypertensive group, haplotype GCAT yielded signifi-
cantly lower values of Scr than GCGC (p=0.0352). The 3-way
haplotype, excluding the first SNP, showed a similar pattern with
CAT being associated with significantly lower values of Scr than
CGC (p=0.0318) and in the last two polymorphisms, AT was
associated with significantly lower Scr than GC (p=0.0293)
(Table 6).
In the normotensive group, the only significant association was
between UACR and the 4-way haplotype. Urine albumin-to-
creatinine ratio was significantly higher in GAAC than in GCAC
(p=0.0482) (Table 7). Linkage disequilibrium (LD) plot of the 4
LEP SNPs and a comparison with LD of the same region in
HapMap YRI population which contains additional markers
across the same span, revealed low pairwise r
2 values indicating
that LD across the region is weak (figure S1).
Discussion
We show from the results of this study that genetic variation in
the LEP could have significant effects on renal disease phenotypes
(markers of renal disease) in indigenous Africans. On the one
hand, a marginal but significant effect was observed on
microalbuminuria in normotensive subjects, while on the other
hand a moderately significant and what is thought to be a
‘‘protective’’ effect was noticed with Scr and eGFR in hypertensive
subjects. The reasons why this gene showed effects only on UACR
Table 2. Characteristics (median and interquartile range) of the study groups.
Hypertensive Normotensive
n Median LQ UQ n Median LQ UQ p-value
Age (yrs) 253 57.0 49.0 63.0 83 32.0 24.0 42.0 ,0.0001
BMI (Kg/m
2) 252 33.7 28.2 39.9 82 28.2 22.1 33.3 0.0002
SBP (mmHg) 252 151.5 137.0 165.3 83 122.0 114.0 138.0 ,0.0001
DBP (mmHg) 252 94.0 87.0 102.0 83 82.0 76.0 89.0 ,0.0001
FBG (mmol/L) 249 5.2 4.8 5.5 82 4.7 4.3 5.1 0.0008
TG (mmol/L) 252 1.2 0.8 1.7 83 0.8 0.6 1.1 0.0292
HDL-c (mmol/L) 252 1.4 1.1 1.6 83 1.5 1.3 1.9 0.0027
Leptin (ng/ml) 247 26.9 11.0 45.5 83 20.0 8.6 35.8 0.0986
Scr (mmol/L) 252 75.0 64.8 89.3 83 66.0 58.5 78.0 0.3067
eGFR(ml/min/1.73 m
2) 252 99.0 85.8 114.0 78 125.0 109.3 143.8 0.1030
UACR (mg/mmol) 252 0.8 0.3 2.6 83 0.6 0.2 1.4 0.0606
P-values are for test of difference in quantile normalised characteristic between diagnostic groups, adjusted for age and gender and relatedness.
n=Number; Interquartile range is lower quartile (LQ) and upper quartile (UQ). BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure;
FBG = fasting blood glucose; TG = triglyceride; HDL-c = high density lipoprotein cholesterol Scr = serum creatinine; eGFR = estimated glomerular filtration rate;
UACR = urinary albumin-to-creatinine ratio.
doi:10.1371/journal.pone.0009086.t002
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hypertensives are presently unclear. However, other factors
associated with the hypertensive state may play a role. Although
we consider that the effects of these polymorphisms on the
phenotypes may be related to the renal actions of serum leptin,
we have not shown that serum leptin has direct effects on the
kidneys and can therefore not exclude autocrine and/or paracrine
mediated actions of leptin in the kidney. The mechanism of
action of serum leptin on the kidney has been previously
described [15].
A number of studies have previously assessed the effects of the
LEP on phenotypes of cardiovascular disease (including obesity)
and cancer [21,22,23,24,25]. However, the results from many
such studies have been largely inconsistent and difficult to replicate
in other populations. For instance, Shintani et al [23] reported a
positive association between a polymorphic tetranucleotide repeat
(TTTC)n polymorphism in the 39 flanking region of the LEP and
hypertension in a group of Japanese patients with essential
hypertension. They found the frequency of the class I allele to
be significantly higher in hypertensives compared with normoten-
sive controls. In two other studies in South Americans and Italians
in which the same polymorphism was examined, there was no
association between the class I/II genotypes or alleles with
hypertension or cardiovascular disease [24,25].
The result of our study may be confirmatory of previous studies
that have reported association between the common polymor-
phisms of the LEP and the various phenotypes they have assayed.
One such confirmation relates to the ‘‘protective’’ effect of the T
allele of the ENSSNP5824596 polymorphism from renal disease.
To our knowledge, only one study [26] has reported on this
‘‘protective’’ effect from atherosclerosis in Caucasians. Gaukrod-
ger et al demonstrated a significantly lower carotid intima medial
thickness and pulse pressure in subjects with the T allele,
compared to subjects without this allele (p=0.0076 and
p=0.0001 respectively) [26]. Our study may have shown that
this so-called ‘‘protective’’ association may exist in a different
population using different phenotypes (Tables 4, 6 and 7).
This study was carried out on the assumption that common
polymorphisms of the LEP may be associated with kidney disease
given that serum leptin has been clinically and pathogenetically
linked with markers of kidney disease [15,16,27]. As we know it,
ESRD is common and more severe in people of African origin,
Table 3. Genotype counts, allele counts and frequency distributions.
Hypertensives Normotensives p-value
nf nf
rs7799039
Typed 191 59
G 358 0.94 113 0.96
A 24 0.06 5 0.04 0.1110
G/G 167 0.87 54 0.92
G/A 24 0.13 5 0.08 0.1110
rs791620
Typed 222 71
C 404 0.91 132 0.93
A 40 0.09 10 0.07 0.5873
C/C 187 0.84 61 0.86
C/A 30 0.14 10 0.14
A/A 5 0.02 0 0 NC
rs2167270
Typed 219 74
A 238 0.54 84 0.57
G 200 0.46 64 0.43 0.8724
A/A 59 0.27 19 0.26
A/G 120 0.55 46 0.62
G/G 40 0.18 9 0.12 0.6912
ENSSNP5824596
Typed 224 77
C 417 0.93 144 0.94
T 31 0.07 10 0.06 0.9286
C/C 193 0.86 68 0.88
C/T 31 0.14 8 0.1
T/T 0 0 1 0.01 NC
P-values are for test of difference in additive allelic and genotype distributions between diagnostic groups, adjusted for age and gender and relatedness.
n = count; f = frequency. NC = could not be calculated, because no minor allele homozygotes observed.
doi:10.1371/journal.pone.0009086.t003
Leptin Gene and Kidney Disease
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socio-economic status, higher prevalence of hypertension and an
increased inherited susceptibility of indigenous Africans to kidney
disease are all possible explanations [28,29]. Additionally, as the
prevalence of obesity continue to increase, its contribution to
kidney disease globally and especially amongst the indigenous
Africans cannot be ignored [30]. The overall median BMI of our
study population was 32.5 kg/m
2 (33.7 kg/m
2 in the hypertensives
and 28.2 kg/m
2 in the normotensive group) (table 2).
This study is important in two ways: firstly, its focus on the
relationship between the LEP and renal disease phenotypes.
However, the value of this is diminished as the only significant
effect we observed after multiple testing was the association of the T
allele at ENNSNP5824596 among the hypertensives. This may
have been due to the smaller sample size in the normotensive group
or due to a possible conditional effect in these subjects with
hypertension and increased BMI. Secondly, it may be important
from the perspective of being carried out in an indigenous African
population with no prior similar studies and in whom similar studies
are generally under-represented. It therefore provides a prospect to
evaluate the relationship between genetic polymorphisms and a
specific complex disease (kidney disease) that is common amongst
indigenous Africans. The study is however limited by its modest
sample size with few SNPs studied and of being a cross-sectional
type. A further and probably a more important limitation to it is our
inability to show that these polymorphisms have any effect on tissue
leptin, especially since we postulated that kidney disease in this
populationis associated with polymorphismsof the LEPthroughthe
renal effects of leptin. To demonstrate that these polymorphisms
affect tissue (renal) leptin will require the design of further
experimental studies. Finally, although modifiable risk factors for
kidney disease are well known, a better understanding of obesity-
related kidney disease will be necessary to control the progression of
chronic renal disease to ESRD in black Africans.
Supporting Information
Table S1 PCR assay of rs7799039
Found at: doi:10.1371/journal.pone.0009086.s001 (0.04 MB
DOC)
Table S2 PCR assay of rs791620
Found at: doi:10.1371/journal.pone.0009086.s002 (0.03 MB
DOC)
Table S3 PCR assay of rs2167270
Found at: doi:10.1371/journal.pone.0009086.s003 (0.03 MB
DOC)
Table S4 PCR assay of ENSSNP5824596
Found at: doi:10.1371/journal.pone.0009086.s004 (0.03 MB
DOC)
Figure S1 Linkage Disequilibrium (LD) plot visualized as a
GOLD heat map
Found at: doi:10.1371/journal.pone.0009086.s005 (1.49 MB TIF)
Table 6. Results of test of association of haplotypes with
markers of renal disease, adjusted for age and gender, in the
hypertensive subjects.
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Scr eGFR UACR
b p b p b p
A C A C 0.29 0.3750 20.41 0.1760 20.03 0.9210
ACGC 20.12 0.7160 0.21 0.5210 20.16 0.6490
G A A C 0.00 0.9870 20.06 0.7420 20.29 0.1480
GCAC 20.04 0.7230 0.07 0.5340 20.08 0.4970
GCAT 20.38 0.0352 0.42 0.0278 20.12 0.5960
-C A T 20.38 0.0318 { 0.42 0.0255 {
--A T 20.36 0.0293 { 0.39 0.0233{
GCGC Base haplotype
Tests are adjusted for age and sex.
b = estimated difference in transformed phenotype between individuals with a
given haplotype and individuals with the base haplotype.
Scr = serum creatinine, eGFR = Estimated Glomerular filtration rate, UACR =
Urine Albumin-to-creatinine ratio.
{- 3 –way haplotype analysis between CAT and CGC.
{- 2 – way haplotype analysis between AT and GC.
doi:10.1371/journal.pone.0009086.t006
Table 5. Inferred haplotype frequencies in the study
population.
Frequency
Haplotype * Hypertensive Normotensive
GCAC 0.37 0.46
GCGC 0.42 0.36
GAAC 0.08 0.07
ACGC 0.04 0.05
GCAT 0.06 0.03
ACAC 0.03 0.00
*- Haplotypes are in their order on chromosome 7 (see Figure 1). Frequencies in
bold characters denote the base (common) haplotypes.
doi:10.1371/journal.pone.0009086.t005
Table 7. Results of tests of association of haplotypes with
markers of renal disease, adjusted for age and gender, in the
normotensive subjects.
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Scr eGFR UACR
b p b p b p
ACGC20.11 0.7650 0.29 0.4920 0.18 0.6835
GAAC20.21 0.4650 0.22 0.4930 0.71 0.0482
GCAT20.28 0.4790 0.45 0.4820 1.35 0.0743
GCGC20.01 0.9480 0.12 0.5380 0.19 0.3194
GCGT20.34 0.4540 0.47 0.3000 20.18 0.6845
GCACBase haplotype
b = estimated difference in transformed phenotype between individuals with a
given haplotype and individuals with the base haplotype.
Scr = Serum creatinine, eGFR = Estimated Glomerular filtration rate, UACR =
Urine Albumin-to-creatinine ratio.
doi:10.1371/journal.pone.0009086.t007
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